FDA Approves Neupro Transdermal Patch Against Parkinson's Disease
Filed in archive Drugs, Vaccines and Therapeutics by ruth on May 10, 2007
Parkinson's disease (PD). Neupro is a once-daily non-ergolinic dopamine agonist skin patch developed by Schwarz Pharma.
"This is an important step forward for the patients suffering from Parkinson's disease. Following approval and launch within Europe, Neupro will now be available for patients in the USA", comments Iris Loew-Friedrich, MD, PhD, CSO SCHWARZ PHARMA AG. "We intend to submit a supplemental New Drug Application for the treatment of advanced Parkinson's disease to the FDA by the end of 2007."Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning.
Source: Schwarz Pharma (pdf)
Permalink: FDA Approves Neupro Transdermal Patch Against Parkinson's Disease
Tags:
FDA Neupro parkinson+disease schwarz+pharma pharma biotech transdermal+patch patch+against
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/68474
